Hidradenitis Suppurativa
Conditions
Brief summary
The binary response status of HiSCR75 (defined as ≥ 75% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count) at Week 16.
Detailed description
Additional endpoints for EU–Treatment-IR Population: HiSCR75 at Week 16. The binary response status of ≥ 1 HS flare during the DBVC period. The binary response status of participants with baseline Skin Pain NRS score ≥ 3 who achieve Skin Pain NRS30 at Week 16. More endpoints in protocol.
Interventions
Sponsors
Incyte Corp.
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The binary response status of HiSCR75 (defined as ≥ 75% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count) at Week 16. | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional endpoints for EU–Treatment-IR Population: HiSCR75 at Week 16. The binary response status of ≥ 1 HS flare during the DBVC period. The binary response status of participants with baseline Skin Pain NRS score ≥ 3 who achieve Skin Pain NRS30 at Week 16. More endpoints in protocol. | — |
Countries
Belgium, Bulgaria, France, Germany, Netherlands, Poland, Spain
Outcome results
None listed